Document Detail


Angina: Ivabradine for treatment of stable angina pectoris.
MedLine Citation:
PMID:  19377492     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The ASSOCIATE study investigators have reported that the I(f) current inhibitor, ivabradine, is safe, improves exercise performance, and delays the development of ischemia in patients with chronic stable angina beingtreated with atenolol. ivabradine should be considered in the medical management of symptom-limited patients with angina, when heart rate is suboptimally controlled.
Authors:
Ranil de Silva; Kim M Fox
Publication Detail:
Type:  News    
Journal Detail:
Title:  Nature reviews. Cardiology     Volume:  6     ISSN:  1759-5010     ISO Abbreviation:  Nat Rev Cardiol     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-04-20     Completed Date:  2009-07-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101500075     Medline TA:  Nat Rev Cardiol     Country:  England    
Other Details:
Languages:  eng     Pagination:  329-30     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use
Angina Pectoris / drug therapy*,  physiopathology
Anti-Arrhythmia Agents / therapeutic use*
Atenolol / therapeutic use
Benzazepines / therapeutic use*
Chronic Disease
Drug Therapy, Combination
Exercise Tolerance / drug effects
Heart Rate / drug effects
Humans
Treatment Outcome
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Anti-Arrhythmia Agents; 0/Benzazepines; 155974-00-8/ivabradine; 29122-68-7/Atenolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Semen analysis in chronic bacterial prostatitis: diagnostic and therapeutic implications.
Next Document:  Valve Disease: Asymptomatic mitral regurgitation: does surgery save lives?